GUILDFORD, SURREY / ACCESS Newswire / March 21, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that, under the Remuneration Policy approved by the shareholders...
UPDATE ON ASTRAZENECA ASSAY DEVELOPMENT PROJECTS AND SUCCESSFUL COMPLETION OF EISAI CONTRACT
NEW RESULTS FOR dual analysis of CTC-DNA and ctDNA using Illumina assay and sequencing platform
CLINICAL TRIAL POWERED BY PARSORTIX SYSTEM PROVIDES FIRST-IN-CLASS data FOR NOVEL APPROACH TO CANCER treatment
Revenue for 2024 expected to be up 31%
WEILL CORNELL MEDICINE PRESENTS HER2 PARSORTIX WORKFLOW AT SAN ANTONIO BREAST CANCER SYMPOSIUM
PARSORTIX-BASED ASSAYS SHOWCASED AT THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH LIQUID BIOPSIES CONFERENCE
PUBLICATION DEMONSTRATES POTENTIAL FOR multi-marker CTC profiling IN EARLY PROSTATE CANCER
Exercise of Options and Total Voting Rights
GUILDFORD, SURREY / ACCESSWIRE / June 29, 2022 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier today,...